PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Ekwuribe et al.

Filed: concurrently herewith Serial No.: to be assigned

For:

Methods of altering the binding affinity of a peptide to its receptor

Date: November 19, 2003

Mail Stop PATENT APPLICATION Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT CITATION UNDER 37 C.F.R. § 1.97

Sir:

Attached are eight sheets of form PTO-1449 as submitted in parent application Serial No. 09/134,803, filed August 14, 1998, with the parent application number, Attorney Docket number and filing date crossed out and the current Attorney Docket number written in. Also attached is a form PTO-1449, providing a list of documents 1-3, previously made of record in application serial number 09/430,735, which is a sister divisional application of the present application that also claims priority to parent application serial number 09/134,803. Because the above-referenced references have already been made of record in these related applications, a copy of each of these references is not provided herein. However, applicants will provide a copy of any such reference cited herein upon request from the Examiner. Also included as item 4 is a reference not previously made of record, and a copy is enclosed. Applicants respectfully request that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. §1.97 and Section 609 of the MPEP.

No fee is believed due. However, the Commissioner is hereby authorized to charge any deficiency or credit any refund to Deposit Account No. 50-0220.

Respectfully submitted.

Mary L. Miller

Registration No. 39,303

USPTO Customer No. 20792Myers Bigel Sibley & Sajovec, P.A.

Post Office Box 37428 Raleigh, NC 27627 Telephone (919) 854-1400

Facsimile (919) 854-1401

CERTIFICATE OF EXPRESS MAILING

Express Mail Label No. EV 353610951 US

Date of Deposit: November 19, 2003

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop PATENT APPLICATION, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Cathy A. Schetzina

FORM PTO-	1449	US Dept. of C		ATTORNEY DOCKET NO).	SERIAL NO		
		Patent and Tra	ademark Office	9232 901	/1L	To be ass	igned	
				4012-113 9233.8DI	<u> </u>	09/134,803 -		
CLIDE	OI EME	NTAL INFORM	ATION	APPLICANT				. 1
~ ~ ~ ~		SURE STATEM		Nnochiri N. Ekwuribe, et al.				
		al sheets if neces		FILING DATE	_	GROUP		
(•	Concurrently herew	ith			
				August 14, 1998		-1646 -		
		T DATES TO	U.S.	PATENT DOCUMENTS		1	FILING	DATE
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	IF APPRO	
	AA	5,693,769	02 Dec 1997	Kahne et al.	536	5		·
					 			
·					1			
		 						
					_		·	
	i					-		
		 	†					
						١.	<u> </u>	
					<u>.</u>			
			1					
	_							
	L	<u></u>		ON DAMENT DOCUMENT		L	L	
	1	DOCUMENT	PUBLICATION	GN PATENT DOCUMENTS	<u> </u>		TRANSI	ATION
		NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
		 	 					
	l							
		OTHER DOCU	MENTS (Includ	ling Author, Title, Journal-I	Date, Page N	umber, Etc.)		
		-						
	<u> </u>			,				
	ļ			<u> </u>		<u> </u>		
					•			
	<u> </u>	<u> </u>		Continue on Page				
				Continue on Page				
EXAMINER					DATE C	ONSIDERED		
				·				
EXAMINER	: Initia	l if citation cons	idered, whether c	or not citation is in conformance	e with MPE	P § 609; Draw	line throug	gh
citation if no	t in con	formance and no	t considered. Inc	clude copy of this form with n	ext communi	cation to the a	pplicant.	

FORM PTO-	1449	US Dept. of Co	ommerce	ATTORNEY DOCKET NO.		SERIAL NO.			
	Patent and Trademark (SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary) NER PATENT AL NUMBER ISSUE DOCUMENT PUBLIC NUMBER DA OTHER DOCUMENTS			4012-113- 9233.8DV4	_	To be ass	ign ed		
				APPLICANT	<u> </u>	09/134,80 3			
SIID	DI EME	NTAL INFORM	ATION	AFFLICAINI					
				Nnochiri N. Ekwuribe, et al					
(us	se sever	al sheets if necess	sary)	FILING DATE		GROUP			
				Concurrently hereunth August 14, 1998	-	1646-			
			U.S.	PATENT DOCUMENTS					
EXAMINER			ISSUE DATE	NAME	CLASS	SUBCLASS	FILING IF APPRO		
INITIAL	<u> </u>	NUMBER	ISSUEDATE	NAME	CLASS	SUBCLASS	II ALLIK	ARATE	
			w ·						
				·					
					-				
		·							
			FOREI	ON PATENT DOCUMENTS					
		ŀ	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	TRANSI YES	LATION NO	
	 	NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	165	110	
	<u> </u>								
		·					ļ		
		OTHER DOCU	MENTS (Includ	ling Author, Title, Journal-Da	te, Page N	umber, Etc.)			
	AA			roperties of PEG-Linked Protein	ns". <i>Critica</i>	ıl Review in Th	ierapeutic	Drug	
	 	Carrier System	3, 7(3, 4) .249-30	J 4 (1772).					
						·			
			·						
									
									
							· · ·	-	
	<u>.l</u>	<u> </u>		Continue on Page					
EXAMINER					DATE C	ONSIDERED			
EXAMINER citation if no	t in con	I if citation consi	dered, whether o	r not citation is in conformance	with MPE	P § 609; Draw	line throu	gh	

FORM PTO-	1449	US Dept. of C	ommerce	ATTORNEY DOCKET N		SERIAL NO		
		Patent and 1 ra	ademark Office	4 012-113 9233.80	14	To be a:	signed	
				APPLICANT		1 03710 1,000		
INFORMAT	ION DI	SCLOSURE ST	ATEMENT					
			>	Nnochiri N. Ekwuribe, et a	1.	GROUP		
(u	se sever	ral sheets if neces	sary)	FILING DATE Concurrently hereu	ith	GROUP		
				August 14, 1998	•	1646-		
			U.S.	PATENT DOCUMENTS		<u> </u>		, n. m
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	IF APPRO	DATE OPRIATE
,	AA	5,932,462	Aug. 3, 1999	Harris et al.	435	188		
-			<u> </u>					
	ļ	<u> </u>						· · · · · · · · · · · · · · · · · · ·
			, , , , , , , , , , , , , , , , , , ,		·	<u> </u>		
						 		
		-	ļ					
		 			_			
	<u> </u>	<u> </u>	FORFIC	I GN PATENT DOCUMENT	rs -	<u> </u>	<u> </u>	
	I	DOCUMENT	PUBLICATION	l l l l l l l l l l l l l l l l l l l			1	LATION
	ļ	NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
			<u> </u>					
		OTHER DOCU	MENTS (Includ	ling Author, Title, Journal-	Date, Page N	umber, Etc.)	<u> </u>	
,			•	•				
								<u>-</u> .
	 							
				· · · · · · · · · · · · · · · · · · ·				
		 						
	I			Continue on Page				
EXAMINER					DATE C	ONSIDERED		
EAMMINER	•			·				
EVANDED). Todaše	l if aitation ages	idered whether a	r not citation is in conforman	ce with MDEI	2 8 609 Draw	line through	zh
citation if no	c. Initia et in con	formance and no	t considered. Inc	clude copy of this form with r	next communic	cation to the a	oplicant.	. ·

	PATER NUMB A 4,585,75 B 4,179,33	U.S. NT ER ISSUE DATE	APPLICANT Nnochiri N. Ekwuribe FILING DATE Chevratly here August 14, 1998 PATENT DOCUMENTS		09/134,803 GROUP	
EXAMINER INITIAL AA AI AI AI AI AI AI AI AI	PATER NUMB A 4,585,75 B 4,179,33	U.S. VT ER ISSUE DATE	FILING DATE Concurrently here. August 14, 1998 PATENT DOCUMENTS	with		
EXAMINER INITIAL AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	PATEI NUMB A 4,585,75 B 4,179,33	U.S. NT ER ISSUE DATE	August 14, 1998 PATENT DOCUMENTS	with		
INITIAL AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	NUMB A 4,585,75 B 4,179,33	NT ER ISSUE DATE	PATENT DOCUMENTS			
INITIAL AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	NUMB A 4,585,75 B 4,179,33	NT ER ISSUE DATE			1070	
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	A 4,585,75 B 4,179,33		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AI AI AI AI AI		1 '	Meisner et al.			
AI AI AI AI	C 4,003,79	7 18 Dec. 1979	Davis et al.			
AI AI AI AI	1 ' '	2 18 Jan. 1977	Mills et al.			
AI AI	D 4,849,40	5 18 Jul. 1989	Ecanow			
AI AI	E 5,013,55	6 7 May 1991	Woodle et al.			
AI	F 4,963,36	7 16 Oct. 1990	Ecanow			
Al	G 4,044,19	6 23 Aug. 1977	Hüper et al.			
	H 4,717,56	6 5 Jan. 1988	Eckenhoff et al.			
A	I 4,698,26	4 6 Oct. 1987	Steinke			
	J 4,684,52	4 4 Aug. 1987	Eckenhoff et al.			
Al	K 4,410,54	7 18 Oct. 1983	Ueno et al.			
Al	L 3,256,15	3 14 Jun. 1966	Heimlich			
Al	M 4,935,24	6 19 Jun. 1990	Ahrens			
Al	N 4,797,28	8 10 Jan 1989	Sharma et al.			
A	O 4,744,97	6 17 May 1988	Snipes et al.			
Al	P 5,055,30	8. Oct. 1991	Makino et al.			
A	Q 5,055,30	00 8 Oct. 1991	Gupta			
Al	R 4,772,47	1 20 Sep. 1988	Vanlerberghe et al.			
A	S 5,093,19	98 3 Mar. 1992	Speaker et al.			
A'	T 4,840,79	9 20 Jun. 1989	Appelgren et al.			
A	U 4,622,39	2 11 Nov. 1986	Hong et al.			
A	V 5,653,98	5 Aug. 1997	Modi et al.			
A.	W 5,792,83	34 11 Aug. 1998	Hakimi et al.			
A	X 5,595,73	32 21 Jan. 1997	Hakimi et al.			
A	Y 5,539,06	53 23 Jul. 1996	Hakimi et al.			
			Continue on page 2			NSIDERED
EXAMINER EXAMINER: Ir						

FORM PTO-	1449	US Dept. of C Patent and Tra	ommerce ademark Office	ATTORNEY DOCKET NO. 4012-113 9233. 8 DI		SERIAL NO To be o 09/134,80 3		ها
INFORMAT	ION DI	SCLOSURE STA	ATEMENT	APPLICANT				
		al sheets if neces		Nnochiri N. Ekwuribe FILING DATE Concorrently here	by herewith GROUP			
		PATENT	<u> </u>	August 14, 1998	1	1646	FILING	DATE
EXAMINER INITIAL		NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	IF APPRO	
	AZ	5,559,213	24 Sep 1996	Hakimi et al.				
	BA	5,747,646	5 May 1998	Hakimi et al.				
	BB	5,286,637	15 Feb. 1994	Veronese et al.				
	BC	5,631,263	20 May 1997	Portoghese et al.				
	BD	5,602,099	11 Feb. 1997	Schiller				
	BE	5,545,719	13 Aug. 1996	Shashoua et al.				
	BF	5,641,861	24 Jun. 1997	Dooley et al.				
	BG	5,663,295	2 Sep. 1997	Moreau et al.				
	ВН	5,786,447	28 Jul. 1998	Schiller et al.				
	BI	4,939,174	3 Jul. 1990	Shashoua				
							<u> </u>	
				GN PATENT DOCUMENTS	<u>S</u>	T	TRANSI	ATION
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
	ВЈ	WO93/01802	4 Feb. 1993	PCT/Switzerland				X
`		OWNER POCH	MENTS (Includ	ling Author, Title, Journal-I	Date Page N	humber, Etc.)		
							ells " Phan	m Res
	BK	Conradi, R.A.,	et al., "The Influ pp. 1453-1459.	ence of Peptide Structure on	Transport Ac	1055 Caco-2 C	Ciis, Tilari	
	BL	Boccu, E. et al	., "Pharmocokine	etic Properties of Polyethylene	Glycol Der	ivatized Supero	oxide Dism	nutase,"
	77.6	Pharm. Res. Co	omm., 1982, 14:	pp. 11-120. Active Peptides Conjugated	with Lecithir	for DDS" Pro	ceed. Inter	n.
	BM	Symp, Cont. R	el. Bioactiv. Mat	er. 1990, 17: pp. 367-368.				
	BN	Taniguchi, T.	et al., "Synthesis	of Acyloyl Lysozyme and Impainistration in Rats," Proceed.	provement of	its Lymphatic Control, Rel	Transport Bioactiv.	Mater
		1992 19: pp. 1	04-105.					
	ВО	Russell-Jones, 1992, 19: pp.	G. J., "Vitamin I	312 Drug Delivery," Proceed.	Intern. Sym	p. Control. Rel	. Bioactive	e. Mater.,
	BP	Baudys, M. et	al., "Synthesis ar	nd Characteristics of Different	Glycosylate	d Derivatives of	of Insulin,"	
	120	Proceed, Intern	n, Symp, Cont. R	el. Bioactiv. Mater., 1992, 19 very Systems, pp. 678-679, M	: pp. 210-21	l		
	BQ	Chien, Y. W.,	Novel Ding Deli	very Systems, pp. 076-077, iv.				
	-A			Continued on page 3				
EXAMINE	₹		***			DATE CO	NSIDEREI) .
EXAMINE	R: Initia	ıl if citation consi	dered, whether o	or not citation is in conformance	ce with MPE	P § 609; Draw	line throug	gh
citation if no	ot in con	formance and no	t considered. Inc	lude copy of this form with ne	ext communic	cation to the ap	piicant.	

FORM PTO-144	19	US Dept. of Commerce	ATTORNEY DOCKET NO.		SERIAL NO.
		Patent and Trademark Office	1010 9222 ONIL	+	To be assigned -09/134,803
		j	4012-113 9233, 8DVL	ı	*************************************
nmon: : ===	(T TO TO	OI OSIDE STATEMENT	APPLICANT		
INFORMATION	N DIS	CLUSUKE STATEMENT	Nnochiri N. Ekwuribe		
(nce c	ATION DISCLOSURE STATEMENT (use several sheets if necessary) BR Pardridge, W.M., "CNS Drown Neurochem., 1998, 70 (5): BS Kroll, R.A., et al., "Outwitting Other Means," 1998 Neurosty Pardridge, W.M., "Blood-Bear Chem Soc. 1995, pp. 265-2 BU Banks, W.A., et al., "Passag Perspectives," Life Sciences Pers	sheets if necessary)	FILING DATE		GROUP
(use si	ic vera	one of the second of the secon	Concurrently herewit	th	
			August 14, 1998		1646
B	R	Pardridge, W.M., "CNS Drug D		ood-Brain	Barrier Transport," J.
		Neurochem., 1998, 70 (5): pp.	1781-1792.	anautic Dec	macaci Ocmatic Opening and
B:	s			apeutic Pu	poses. Osmone Opening and
	- +	Described W.M. "Pland Brain	Rarrier Pentide Transport and P	Pentide Dru	Delivery to the Brain." Amer.
B	1	Chem Soc 1995 pp. 265-296	Darrier replice transport and r	opado Dit	-0 ,
R	TT	Banks, W.A., et al., "Passage of	Peptides Across the Blood-Brai	in Barrier:	Pathophysiological
" "	٦	Perspectives," Life Sciences, 19	96, 59 (23), pp: 1923-1943.		<u> </u>
В	v	Fix, J.A., "Oral Controlled Rele	ase Technology for Peptides: Sta	atus and Fu	iture Prospects," Pharm. Res.,
		1996, 13 (12); pp: 1760-1763.			
В	W	Terasaki, T., et al., "Oligopeption			
В	$\frac{1}{x}$	Bodor, N., et al., "Molecular Pa	ckaging. Peptide Delivery to the	e Central N	Vervous System by Sequential
		Metabolism." Amer. Chem. Soc	: 1995, p:317-337.	•	
В	Y				
B	z	Santiago, N. et al., "Oral Immur	nization of Rats with Influenze V	irus M Pro	otein (M1) Microspheres,"
		Proceed. Intern. Symp. Cont. Re	el. Bioactiv. Mater., 1992, 19: p	р. 116-117	7
C	:A	Banting, R. G., et al., "Pancreat	ic Extracts in the Treatment of D	Diabetes Me	ellitus," The Canadian Med.
		Assoc. J. 1922, 12: pp. 141-146	5.		During Storage of
C:	B	Brange, J. et al., "Chemical State	bility of Insulin. 1. Hydrolytic D	egradation 5-726	During Storage of
<u> </u>	, 	Musci et al "The Theraneutic	Value of Poly(ethylene glycol) -	Modified	Proteins," Ac. Drug. Del. Rev.
	.	1991, 6: pp. 133-151.			
 	D	Brange, J. et al., "Chemical Stat	bility of Insulin. 2. Formation of	Higher Mo	olecular Weight Transformation
	-	Products During Storage of Pha	rmaceutical Preparations," Phart	m. Res., 19	992, 9 (6): pp. 727-734.
C	E	Robbins, D. C. et al., "Antibodi	es to Covalent Aggregates of Ins	sulin in Blo	ood of Insulin-Using Diabetic
		Patients," Diabetes, 1987, 36: 1	op. 838-841.	Toronti e i e 7	Time I Dishatia Patients is
C	F	Maislos, M. et al., "The Source	of the Circulating Aggregate of	insuin in	Type I Diabetic Fatients is
	,	Inerapeutic Insulin," J. Clin. In	Cutaneous Insulin Alleray Decul-	ting from F	High-Molecular Weight Insulin
C	.G	Aggregates "Diabetes 1000 30	Outaneous misumi Amergy Resur	une nom I	
 	, H	Oka K et al "Enhanced Intest	inal Absorption of a Hydrophob	ic Polymer	-Conjugated Protein Drug,
	,11	Smanes in an Oily Formulation	" Pharm. Res., 1990, 7 (8): pp.	. 852-855.	
l c	I	Saffran, M. et al., "A New Appr	roach to the Oral Administration	of Insulin	and Other Peptide Drugs,"
		Science 1986 233 pp. 1081-1	1084.		
C	CJ	Abuchowski, A. and F. F. Davis	s, "Soluble Polymer-Enzyme Ad	lducts," pp.	. 368-383, Enzymes as Drugs, J.
		S. Holcenberg, John Wiley, 198	31.	D. A1-1 4	Cham
C	CK	Akiyama, M. et al., "The Synthe	esis of New Derivatives of 1-β-I	J-Arabinol	uranosylcylosine, Chem.
	 	Pharm. Bull., 1978, 26(3): p. 98	de 11 Complesses of 5' Estare of	1-B-D-Ara	binofuranosylcytosine Possessing
C	IL .	Gish, D. T. et al., "Nucleic Acid	ressive Activity," J. Med. Chem.	1971. 14	(12): pp. 1159-1162.
<u> </u>	1	Antheukeniic and immunosupp	Continue on Page 4	., · - · · ·	V. / FF
			Collemne on 1 ago 4	DATE C	ONSIDERED
EXAMINER		· .		DATEC	ONGIDERED
EXAMINER: I	nitial	if citation considered, whether o	r not citation is in conformance	with MPEI	9 § 609; Draw line through
citation if not in	confe	ormance and not considered. Inc	lude copy of this form with next	t communic	cation to the applicant.

FORM PTO-	1449	US Dept. of Commerce	ATTORN	VEY DOCKET NO.	SERIAL NO.
		Patent and Trademark Office		9233.8DV4	To be assigned
					09/134,803-
DIFORMATION CASE	יים זאטז	COLOCUDE STATEMENT	APPLICA	JINI	
INFORMAT	ION DE	SCLOSURE STATEMENT	Nnochiri	N. Ekwuribe	
l	se sever	al sheets if necessary)	FILING I	DATE	GROUP
(u.			Concur	rently herewith	
			August 1	4, 1998	1646
				mul I Did Dee N	Tto
		OTHER DOCUMENTS (Includ	ing Author	r, Title, Journal-Date, Page N	umber, Etc.)
	CM	Baker, D. C. et al., "Prodrugs of (O-Acyl) Derivatives," J. Med.	[9-β-D-Ara Cham 107	abinofuranosyladenine. 1. Synus	esis and Evaluation of Some 5'-
	CN	Hostetler, K. Y. et al., "Synthes	is and Anti	retroviral Activity of Phospholi	oid Analogs of Azidothymidine
	Civ	and Other Antiviral Nucleosides	s," The Jou	rnal of Biological Chemistry, 19	990, 265(11): pp. 6112-6117.
	со	Hong, C. I. et al., "Nucleoside C	Conjugates.	7. Synthesis and Antitumor Ac	tivity of 1-β-D-
		Arabinofuranosylcytosine Conju	igates of E	ther Lipids," J. Med. Chem., 19	86, 29: pp. 2038-2044.
	CP	Aoshima, M. et al., "N4-Beheno	yl-1-β-D- <i>A</i>	rabinofuranosylcytosine as a Pe	otential New Antitumor Agent,"
		Cancer Research, 1977, 37: pp.	2481-2480	5.	olum I 1082 10/12); nn 1177
·	CQ	1183.			olym. J., 1983, 19(12): pp. 1177-
	CR	Tsuzuki, N., et al., "Rabid Com	munication	. Adamantane as a Brain-Direc	ted Drug Carrier for Poorly
		Absorbed Drug: Antinociceptiv	e Effects of	f [D-Ala2] Leu-Enkephalin Deri	vatives Conjugated with the 1-
		Adamantane Moiety," Biochem	ical Pharm	acology, 1991, 41 (4): pp. R5-R	Develophermacology: The
	CS	Wagner, J., et al., "Neuropharm Fourth Generation of Progress,	acology of	Endogenous Opioid Pepudes, 19-529.	i sychopharmacology. The
	CT	Horvat, J., et al., "Synthesis and	Biologica	Activity of [Leu ⁵] Enkephalin	Derivatives Containing D-
		Glucose," J. Peptide Protein Re	s., 1988, 31	l, pp: 499-507.	
	CU	Shashoua V.E., et al., "y-Amino	butyric Ac	id Esters. 1. Synthesis, Brain U	ptake, and Pharmacological
		Studies of Aliphatic and Steroic	Esters of	/-Aminobutyric Acid," J. Med.	Chem., 1984, 27 (5), pp: 660-
	-	664. Brewster, M., et al., "Tissue Dis	-mihartian a	f I V221617 an Antiovidant wi	th Neuroprotectant Activity in
	CV	the Rat " I Pharm Studies " 19	95. 84 (7).	pp: 791-793.	
	CW	Chen, C., et al., "Extensive Bili	ary Excreti	on of the Model Opioid Peptide	[D-PEN ^{2,5}] Enkephalin in Rats,"
	``'	Pharm, Res. J., 14, pp: 345-350	•		
	CX	Bodor, N., et al., "A Strategy for	r Deliverin	g Peptides into the Central Ner	vous System by Sequential
		Metabolism," Science, 1992, 25	7, pp: 169	8-1702.	s in Dat Brain by Aganist
	CY	Sim, L., et al., "In vitro Autorac stimulated Guanylyl 5'-[γ[³⁵ S]th	nography c	sphere Rinding "Proc. Natl. Ac	s in Kat Drain by Agonist-
		7242 7246		•	
	CZ	Weber S.L. et al., "Whole Bod	y and Brain	Distribution of [3H]Cyclic [D-	PEN ² , D-PEN ⁵] Enkephalin after
		Intraperitoneal, Intravenous, Or	al and Sub	cutaneous Administration," J. P.	harm. Exper. Ther., 1992, 263
		pp: 1308-1316		•	
	DA	Alyautdin, R.N., "Delivery of L	operamide	Across the Blood-Brain Barrier	with Polysorbate 80-Coated
		Polybutylevanoacrylate Nanopa	irticles," Ph	narm. Res. J., 1997, 14, pp: 325	-328.
	DB	Chiou, G.C.Y., et al., "Systemic	Delivery (or Enkephanin repude unough i	syes, Life defences, 1700, 43,
	DC	pp: 509-514.	n with I -G	lutamic Acid for Brain Drug De	livery," Proceed. Intern. Symp.
	שלו	Control. Rel. Bioact. Mater., 19	66, 23, pp:	607-608.	
	<u> </u>	1 - x		on Page 5	.
EXAMINER)			DATE CONSIDERED	
EVVIATINE					
					D 0 (00 D)
EXAMINER	: Initia	l if citation considered, whether o	r not citatio	on is in conformance with MPE	9 § 609; Draw line through
citation if no	t in con	formance and not considered. Inc	lude copy	of this form with next communi	саноп ю ше аррисань.

FORM PTO-1449	US Dept. of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO. 4012-113 9233.80V	SERIAL NO. To De assigned t 09/134,803
INFORMATION D	ISCLOSURE STATEMENT	APPLICANT	
	ral sheets if necessary)	Nnochiri N. Ekwuribe FILING DATE	GROUP
	·	Concurrently heneus August 14, 1998	1646
DD	Degradation in Various Rabbit	Mucosa Extracts," J. Pharm.Sci.	halin. I: Solution Stability and Kinetics of , 1993, 82 (4), pp: 373-378.
DE	Brewster, M.E., et al., "Efficacy Estradiol Brain Targeting." J. P	of a 3-Substituted Versus 17-S harm. Sci., 1994, pp: A-E.	ubstiturted Chemical Delivery System for
DF	Mosnaim, A.D., et al., "Studies	of the in Vitro Human Plasma I	Degradation of Methionine-Enkephalin,"
DG	Weber, S.J., et al., "Distribution Halogenated Analogs after Intra	n and Analgesia of [³ H][D-PEN ⁴ avenous Administration," J. Pha	, D-PEN ⁵] Enkephalin and Two m. Exper. Ther., 1991, 259, pp: 1109-
DH	Brewster, M.E., et al., "Effect of	stem," J. Med. Chem., 1994, 37	Estrogenic Activity of a Brain-Targeting pp: 4237-4244
DI	Pardridge, W.M., "New Approx Biotechnology, 1994, pp: 239-2	aches to Drug Delivery Through 245.	the Blood-Brain Barrier," Trends in
DJ	Shashoua, V.E., et al., "N-Doco	osahexaenoyl, 3 Hydroxytyramir rier and Suppresses Appetite," I	e: A Dopaminergic Compound that ife Sciences, 58 (16), pp: 1347-1354.
· DK	Gibson, A.M., et al., "Specificity and Dynorphin-Related Peptide	ty of Action of Human Brain Ales." Neuropeptides, 1989, 13, pp	inyl Aminopeptidase on Leu-Enkephalin: 259-262.
DL	Prokai-Tatrai, K., et al., "Brain- Design," J. Med. Chem, 1996,	-Targeted Delivery of a Leucine	Enkephalin Analogue by Retrometabolic
		Continue on Page	
EXAMINER			DATE CONSIDERED
EXAMINER: Initial citation if not in con-	al if citation considered, whether of a formance and not considered. Inc.	r not citation is in conformance clude copy of this form with nex	with MPEP § 609; Draw line through communication to the applicant.

Substitute	form 1449A/PTO			С	omplete if Kn wn
				Application Number	To be assigned
INFORM	ATION DISCL	.OSURI		Filing Date	Concurrently herewith
STATEM	ENT BY APPI	LICANT	Ī	First Named Inventor	Ekwurib
(use as ma	ny sheets as nec	essary)			
Sheet	1	of	1	Attorney Docket Number	9233.8DV4

	·		U.S. PATENTS	AND PATENT PUBLICATIONS	
Examiner Initials*	Cite No.	U.S. Patent		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
HIIIIII		Number	Kind Code (if known)	Document	MM-DD-YYYY
	1.	5,061,691		Yagi et al.	10-29-1991
	2.	5,428,128		Mensi-Fatthoi et al.	06-27-1995
	3.	6,309,633		Ekwuribe et al	10-30-2001
				-	-
		<u> </u>	[<u> </u>	•

				FOREIGN PA	ATENT DOCUMENTS		
Examiner Cite Initials* No.		Foreign Patent D	ocument	Name of Patentee or Applicant of Cited Document	Date of Publication	Т	
miliais	itials* No. Offic	Office	Number	Kind Code (if known)	Document	of Cited Document MM-DD-YYYY	
	-						
	ļ						

		OTHER NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Т
	4.	Anderson et al. "Structure-Activity Relationship Assessment of Conjugated Enkephalins in Centrally Mediated Analgesia" Soc. Neurosci. Abstr. 25(1):180 (1999)	
	-		
			1

Examiner Signature			Date Considered	
	<u> </u>			
ACTION A 111 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1				